Abiopharma

🔍 Ware Olivia C (Executive)

Company: Arcellx, Inc. (ACLX)

Report Date: 2026-04-28

Detailed Transactions and Holdings:

• Sold 36,806 shares of Stock Option (right to buy) at $7.61 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2032-05-16 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 11,459 shares of Stock Option (right to buy) at $37.94 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2033-06-14 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 8,011 shares of Stock Option (right to buy) at $51.3 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2034-05-28 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 9,174 shares of Stock Option (right to buy) at $63.68 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2035-05-29 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1

Footnotes:

• F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.